Comparison of genotype frequencies of TNFRSF11A single nucleotide polymorphisms in patient and the control groups_
| SNPs | Allele | Patient Group n (%) | Control Group n (%) | p Value |
|---|---|---|---|---|
| rs4941129 | TT | 26 (51.0) | 29 (52.7) | 0.329 |
| CT | 23 (45.1) | 20 (36.4) | ||
| CC | 2 (3.9) | 6 (10.9) | ||
| rs884205 | CC | 29 (56.9) | 35 (63.6) | 0.104 |
| AC | 18 (35.3) | 20 (36.4) | ||
| AA | 4 (7.8) | 0 (0.0) | ||
| rs17069904 | GG | 40 (78.4) | 49 (89.1) | 0.297 |
| AG | 10 (19.6) | 5 (9.1) | ||
| AA | 1 (2.0) | 1 (1.8) | ||
| rs34739845 | AA | 40 (78.4) | 36 (65.5) | 0.331 |
| AG | 10 (19.6) | 17 (30.9) | ||
| GG | 1 (2.0) | 2 (3.6) | ||
| rs9646629 | GG | 19 (37.3) | 26 (47.3) | 0.546 |
| CG | 24 (47.1) | 23 (41.8) | ||
| CC | 8 (15.7) | 6 (10.9) | ||
| rs4485469 | AA | 14 (27.5) | 13 (23.6) | 0.820 |
| AG | 22 (43.1) | 27 (49.1) | ||
| GG | 15 (29.4) | 15 (23.7) |
Comparison of the relationship between estrogen receptor status and TNFRSF11A single nucleotide polymorphisms in the patients groups_
| SNPs | Alleles | Patients With BRCA1 or BRCA2 Mutations | Patients Without BRCA1 or BRCA1 2 Mutations | ||||
|---|---|---|---|---|---|---|---|
| Negative ER n (%) | Positive ER n (%) | p Value | Negative ER n (%) | Positive ER n (%) | p Value | ||
| rs4941129 | TT | 2 (25.0) | 4 (50.0) | 3 (50.0) | 11 (50.0) | 0.863 | |
| CT | 6 (75.0) | 3 (37.5) | 0.100 | 3 (50.0) | 10 (45.5) | ||
| CC | 0 (0.0) | 1 (12.5) | 0 (0.0) | 1 (4.5) | |||
| rs884205 | CC | 6 (75.0) | 4 (50.0) | 3 (50.0) | 12 (54.5) | 0.675 | |
| AC | 2 (25.0) | 4 (50.0) | 0.153 | 3 (50.0) | 8 (36.4) | ||
| AA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (9.1) | |||
| rs17069904 | GG | 7 (87.5) | 6 (75.0) | 5 (83.3) | 18 (81.8) | 0.932 | |
| AG | 1 (12.5) | 2 (25.0) | 0.516 | 1 (16.7) | 4 (18.2) | ||
| AA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| rs34739845 | AA | 7 (87.5) | 7 (87.5) | 5 (83.3) | 17 (77.3) | 0.860 | |
| AG | 1 (12.5) | 1 (12.5) | 0.267 | 1 (16.7) | 4 (18.2) | ||
| GG | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.5) | |||
| rs9646629 | GG | 5 (62.5) | 2 (25.0) | 1 (16.7) | 7 (31.8) | 0.223 | |
| CG | 3 (37.5) | 5 (62.5) | 0.205 | 5 (83.3) | 10 (45.5) | ||
| CC | 0 (0.0) | 1 (12.5) | 0 (0.0) | 5 (22.7) | |||
| rs4485469 | AA | 5 (62.5) | 4 (50.0) | 0 (0.0) | 4 (18.2) | 0.512 | |
| AG | 2 (25.0) | 2 (25.0) | 0.413 | 4 (66.7) | 11 (50.0) | ||
| GG | 1 (12.5) | 2 (25.0) | 2 (33.3) | 7 (31.8) | |||
Comparison of genotype frequencies of TNFRSF11A single nucleotide polymorphisms between patient groups with and without BRCA1 or BRCA2 mutations_
| SNPs | Allele | Patients With Mutations n (%) | Patients Without Mutations n (%) | p Value |
|---|---|---|---|---|
| rs4485459 | AA | 10 (43.5) | 4 (14.3) | 0.059 |
| AG | 7 (30.4) | 15 (53.6) | ||
| GG | 6 (26.1) | 9 (32.1) | ||
| rs9646629 | GG | 11 (47.8) | 8 (28.6) | 0.367 |
| CG | 9 (39.1) | 15 (53.6) | ||
| CC | 3 (13.0) | 5 (17.9) | ||
| rs34739845 | AA | 18 (78.3) | 22 (78.6) | 0.632 |
| AG | 5 (21.7) | 5 (17.9) | ||
| GG | 0 (0.0) | 1 (3.6) | ||
| rs17069904 | GG | 17 (73.9) | 23 (82.1) | 0.491 |
| AG | 5 (21.7) | 5 (17.9) | ||
| AA | 1 (4.3) | 0 (0.0) | ||
| rs884205 | CC | 14 (60.9) | 15 (53.6) | 0.804 |
| AC | 7 (30.4) | 11 (39.3) | ||
| AA | 2 (8.7) | 2 (7.1) | ||
| rs4941129 | TT | 12 (52.2) | 14 (50.0) | 0.973 |
| CT | 10 (43.5) | 13 (46.4) | ||
| CC | 1 (4.3) | 1 (3.6) |
Comparison of the relationship between the TNFRSF11A single nucleotide polymorphisms and metastasis status in the patient group with and without BRCA1 or BRCA2 mutations_
| SNPs | Allele | Patients With Neg. Metastasis n (%) | Patients With Pos. Metastasis n (%) | p Value |
|---|---|---|---|---|
| rs4941129 | TT | 9 (52.9) | 12 (42.9) | 0.463 |
| CT | 7 (41.2) | 15 (53.6) | ||
| CC | 1 (5.9) | 1 (3.6) | ||
| rs884205 | CC | 7 (41.2) | 19 (67.9) | 0.352 |
| AC | 9 (52.9) | 7 (25.0) | ||
| AA | 1 (5.9) | 2 (7.1) | ||
| rs17069904 | GG | 13 (76.5) | 23 (82.1) | 0.718 |
| AG | 4 (23.5) | 4 (14.3) | ||
| AA | 0 (0.0) | 1 (3.6) | ||
| rs34739845 | AA | 12 (70.6) | 24 (85.7) | 0.471 |
| AG | 4 (23.5) | 4 (14.3) | ||
| GG | 1 (5.9) | 0 (0.0) | ||
| rs9646629 | GG | 3 (17.6) | 13 (46.4) | 0.348 |
| CG | 11 (64.7) | 11 (39.3) | ||
| CC | 3 (17.6) | 4 (14.3) | ||
| rs4485469 | AA | 4 (23.5) | 10 (35.7) | 0.365 |
| AG | 9 (52.9) | 10 (35.7) | ||
| GG | 4 (23.5) | 8 (28.6) |
Comparison of the relationship between progesterone receptor status and TNFRSF11A single nucleotide polymorphisms in the patient groups_
| SNPs | Alleles | Patients With BRCA1 or BRCA2 Mutations | Patients Without BRCA1 or BRCA2 Mutations | ||||
|---|---|---|---|---|---|---|---|
| Negative PR n (%) | PR Positive n (%) | p Value | Negative PR n (%) | PR Positive n (%) | p Value | ||
| rs4941129 | TT | 4 (36.4) | 2 (40.0) | 3 (37.5) | 11 (55.0) | 0.503 | |
| CT | 7 (63.6) | 2 (40.0) | 0.085 | 5 (62.5) | 8 (40.0) | ||
| CC | 0 (0.0) | 1 (20.0) | 0 (0.0) | 1 (5.0) | |||
| rs884205 | CC | 7 (63.6) | 3 (60.0) | 4 (50.0) | 11 (55.0) | 0.562 | |
| AC | 4 (36.4) | 2 (40.0) | 0.242 | 4 (50.0) | 7 (35.0) | ||
| AA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (10.0) | |||
| rs17069904 | GG | 10 (90.9) | 3 (60.0) | 5 (62.5) | 18 (90.0) | 0.086 | |
| AG | 1 (9.1) | 2 (40.0) | 0.304 | 3 (37.5) | 2 (10.0) | ||
| AA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| rs34739845 | AA | 10 (90.9) | 4 (80.0) | 6 (75.0) | 16 (80.0) | 0.691 | |
| AG | 1 (9.1) | 1 (20.0) | 0.237 | 2 (25.0) | 3 (15.0) | ||
| GG | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.0) | |||
| rs9646629 | GG | 6 (54.5) | 1 (20.0) | 3 (37.5) | 5 (25.0) | 0.290 | |
| CG | 5 (45.5) | 3 (60.0) | 0.220 | 5 (62.5) | 10 (50.0) | ||
| CC | 0 (0.0) | 1 (20.0) | 0 (0.0) | 5 (25.0) | |||
| rs4485469 | AA | 6 (54.5) | 3 (60.0) | 0 (0.0) | 4 (20.0) | 0.069 | |
| AG | 2 (18.2) | 2 (40.0) | 0.276 | 7 (87.5) | 8 (40.0) | ||
| GG | 3 (27.3) | 0 (0.0) | 1 (12.5) | 8 (40.0) | |||
The demographic data of the patients (with and without BRCA1 or BRCA2 mutations) and the control group_
| Parameters | n | Mean±SD | Minimum | Maximum |
|---|---|---|---|---|
| Patient group with BRCA1 or BRCA2 mutations | 23 | 45.13±13.73 | 24.00 | 76.00 |
| Patient group without BRCA1 or BRCA2 mutations | 28 | 44.54±8.28 | 33.00 | 62.00 |
| Patient group with and without BRCA1 or BRCA2 mutations | 51 | 44.80±10.97 | 24.00 | 76.00 |
| Control group | 55 | 44.00±8.11 | 41.00 | 72.00 |
Comparison of the relationship between metastasis status and TNFRSF11A single nucleotide polymorphisms in the patient groups_
| SNPs | Alleles | Patients With BRCA1 or BRCA2 Mutations | Patients Without BRCA1 or BRCA2 Mutations | ||||
|---|---|---|---|---|---|---|---|
| Negative Metastasis n (%) | Positive Metastasis n (%) | p Value | Negative Metastasis n (%) | Positive Metastasis n (%) | p Value | ||
| rs4941129 | TT | 3 (50.0) | 4 (36.4) | 6 (54.5) | 8 (47.1) | 0.696 | |
| CT | 2 (33.3) | 7 (63.6) | 0.156 | 5 (45.5) | 8 (47.1) | ||
| CC | 1 (16.7) | 0 (0.0) | 0 (0.0) | 1 (5.9) | |||
| rs884205 | CC | 3 (50.0) | 8 (72.7) | 4 (36.4) | 11 (64.7) | 0.338 | |
| AC | 3 (50.0) | 2 (18.2) | 0.598 | 6 (54.5) | 5 (29.4) | ||
| AA | 0 (0.0) | 1 (9.1) | 1 (9.1) | 1 (5.9) | |||
| rs17069904 | GG | 4 (66.7) | 9 (81.8) | 9 (81.8) | 14 (82.4) | 0.971 | |
| AG | 2 (33.3) | 1 (9.1) | 0.588 | 2 (18.2) | 3 (17.6) | ||
| AA | 0 (0.0) | 1 (9.1) | 0 (0.0) | 0 (0.0) | |||
| rs34739845 | AA | 5 (83.3) | 9 (81.8) | 7 (63.6) | 15 (88.2) | 0.228 | |
| AG | 1 (16.7) | 2 (18.2) | 0.724 | 3 (27.3) | 2 (11.8) | ||
| GG | 0 (0.0) | 0 (0.0) | 1 (9.1) | 0 (0.0) | |||
| rs9646629 | GG | 2 (33.3) | 6 (54.5) | 1 (9.1) | 7 (41.2) | 0.161 | |
| CG | 4 (66.7) | 3 (27.3) | 0.550 | 7 (63.6) | 8 (47.1) | ||
| CC | 0 (0.0) | 2 (18.2) | 3 (27.3) | 2 (11.8) | |||
| rs4485469 | AA | 4 (66.7) | 6 (54.5) | 0 (0.0) | 4 (23.5) | 0.138 | |
| AG | 1 (16.7) | 3 (27.3) | 0.158 | 8 (72.7) | 7 (41.2) | ||
| GG | 1 (16.7) | 2 (18.2) | 3 (27.3) | 6 (35.3) | |||
Comparison of the relationship between CerbB2 receptor status and TNFRSF11A single nucleotide polymorphisms in the patient groups_
| SNPs | Alleles | Patients With BRCA1 or BRCA2 Mutations | Patients Without BRCA1 or BRCA2 Mutations | ||||
|---|---|---|---|---|---|---|---|
| Neg. CerB2 Receptor n (%) | Pos. CerB2 Receptor n (%) | p Value | Neg. CerB2 Receptor n (%) | Pos. CerB2 Receptor n (%) | p Value | ||
| rs4941129 | TT | 4 (50.0) | 2 (28.6) | 7 (43.8) | 7 (58.3) | 0.564 | |
| CT | 3 (37.5) | 5 (71.4) | 0.250 | 8 (50.0) | 5 (41.7) | ||
| CC | 1 (12.5) | 0 (0.0) | 1 (6.3) | 0 (0.0) | |||
| rs884205 | CC | 4 (50.0) | 5 (71.4) | 8 (50.0) | 7 (58.3) | 0.852 | |
| AC | 4 (50.0) | 2 (28.6) | 0.207 | 7 (43.8) | 4 (33.3) | ||
| AA | 0 (0.0) | 0 (0.0) | 1 (6.3) | 1 (8.3) | |||
| rs17069904 | GG | 6 (75.0) | 6 (85.7) | 14 (87.5) | 9 (75.0) | 0.393 | |
| AG | 2 (25.0) | 1 (14.3) | 0.661 | 2 (12.5) | 3 (25.0) | ||
| AA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| rs34739845 | AA | 7 (87.5) | 6 (85.7) | 12 (75.0) | 10 (83.3) | 0.292 | |
| AG | 1 (12.5) | 1 (14.3) | 0.407 | 4 (25.0) | 1 (8.3) | ||
| GG | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (8.3) | |||
| rs9646629 | GG | 3 (37.5) | 3 (42.9) | 4 (25.0) | 4 (33.3) | 0.890 | |
| CG | 5 (62.5) | 3 (42.9) | 0.278 | 9 (56.3) | 6 (50.0) | ||
| CC | 0 (0.0) | 1 (14.3) | 3 (18.8) | 2 (16.7) | |||
| rs4485469 | AA | 4 (50.0) | 4 (57.1) | 2 (12.5) | 2 (16.7) | 0.540 | |
| AG | 1 (12.5) | 3 (42.9) | 0.291 | 10 (62.5) | 5 (41.7) | ||
| GG | 3 (37.5) | 0 (0.0) | 4 (25.0) | 5 (41.7) | |||